MEDIROM Healthcare Technologies (MRM) Fundamentals 2026 — Revenue Analysis | SniperIQ
MEDIROM Healthcare Technologies (MRM) is a JP-listed Consumer Cyclical company in Personal Products & Services with a market capitalization of $5M, trading at $0.96 on the NASDAQ. This SniperIQ fundamentals page covers MEDIROM Healthcare Technologies's valuation, profitability (net margin -16.1%), revenue (¥4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MEDIROM Healthcare Technologies's market cap?
MEDIROM Healthcare Technologies (MRM) has a market capitalization of approximately $5M, trading at $0.96 on the NASDAQ. Market cap moves with the live share price.
What is MEDIROM Healthcare Technologies's P/E ratio?
MEDIROM Healthcare Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.
How profitable is MEDIROM Healthcare Technologies?
MEDIROM Healthcare Technologies runs a net profit margin of -16.1%, a gross margin of 25.3%, and an operating margin of -19.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MEDIROM Healthcare Technologies generate?
MEDIROM Healthcare Technologies reported revenue of ¥4M for fiscal year 2025, with net income of ¥374,720 and earnings per share (EPS) of 7.43. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MEDIROM Healthcare Technologies pay a dividend?
MEDIROM Healthcare Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MEDIROM Healthcare Technologies financially healthy?
MEDIROM Healthcare Technologies carries a debt-to-equity ratio of 1.75x and a current ratio of 1.75x, with a market beta of 1.01. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MEDIROM Healthcare Technologies a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MEDIROM Healthcare Technologies (MRM) the key facts are: market cap $5M, revenue ¥4M, 52-week range 0.9-4.45. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.
Track MEDIROM Healthcare Technologies's full fundamentals live
Get MEDIROM Healthcare Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.